Publications by authors named "Katarina Kovacevic Miljevic"
Drugs targeting factor XI may offer an alternative to heparin for preventing blood clotting in extracorporeal circulation. We investigated the effects of abelacimab, a novel monoclonal antibody targeting factor XI. We collected whole blood samples into two bags (each 240 ml, control group: enoxaparin 1.
View Article and Find Full Text PDFIntroduction: Hemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a prospective multicenter study to investigate the pharmacokinetics and pharmacodynamics of clopidogrel in HDPs and healthy volunteers (HVs).
View Article and Find Full Text PDFBackground: Recombinant tissue plasminogen activator (rt-PA) is a thrombolytic agent and essential in emergency medical care. Given recent supply shortages, the availability of biosimilar products is an urgent medical need. However, biosimilarity trials are difficult to perform in critically ill patients.
View Article and Find Full Text PDFArticle Synopsis
- Leaflet thrombosis (LT) is a complex and poorly understood complication that can occur after transcatheter aortic valve implantation (TAVI), prompting the need for better prediction models to identify at-risk patients.
- A study involving 101 TAVI patients utilized imaging and lab tests to determine various clinical and biological factors associated with LT, discovering that certain elevated and decreased lab values could predict its occurrence.
- The researchers created an EFFORT score to quantify the risk, finding that patients scoring 2 or higher had an 85.7% likelihood of developing LT, indicating the score's potential as a powerful tool for risk assessment post-TAVI.